Guidelines: Finnish Breast Cancer Association Guideline (Finland): Difference between revisions
m (Update categories.) |
m (Update categories.) |
||
| Line 27: | Line 27: | ||
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | ||
<span style="display:none">hasCancerType::C00-C97: All cancer types</span> | <span style="display:none">hasCancerType::C00-C97: All cancer types</span> | ||
<span style="display:none">Axilla</span> | |||
<span style="display:none">Axillary</span> | |||
<span style="display:none">Mammary</span> | |||
Latest revision as of 12:03, 14 December 2025
Go back to Finland page
Primary purpose: To provide comprehensive, evidence-based recommendations for the diagnosis, treatment, and follow-up care of breast cancer patients to ensure optimal patient outcomes and standardized clinical practices.
Sponsor, manager or home institution: Finnish Breast Cancer Group.
Type of information: medical procedures, screening, cancer prevalence, risk of cancer, palliative care. Provides comprehensive guidelines on breast cancer, covering diagnostic pathways, staging, triple diagnostics, imaging follow-up, hereditary breast cancer, core needle biopsy, multidisciplinary treatment planning, surgical and reconstruction options, radiotherapy, neoadjuvant and adjuvant drug treatments, hormonal therapies, chemotherapy, management of recurrent and metastatic breast cancer, special cases like pregnancy, and follow-up care. Click here to learn more.
Cancer areas of interest: C50: Breast cancer. Click here to learn more.
Access to information: Click here to access.